The genetic concept of synthetic lethality provides a framework for identifying genotype-selective anticancer agents. In this approach, changes in cellular physiology that arise as a consequence of oncogene activation or tumor suppressor gene loss, rather than oncoproteins themselves, are targeted to achieve tumor selectivity. Here we show that agonists of the TRAIL death receptor DR5 potently induce apoptosis in human cells overexpressing the MYC oncogene, both in vitro and as tumor xenografts in vivo. MYC sensitizes cells to DR5 in a p53-independent manner by upregulating DR5 cell surface levels and stimulating autocatalytic processing of procaspase-8. These results identify a novel mechanism by which MYC sensitizes cells to apoptosis and validate DR5 agonists as potential MYC-selective cancer therapeutics.
Introduction
tumor cells to be killed preferentially over normal cells. Agents that could exploit this hypersensitivity would achieve tumor specificity by a mechanism distinct from directly targeting onco-The MYC proto-oncogene encodes a basic helix loop helix zipper (bHLHZ) domain-containing transcription factor that plays protein function, as molecularly targeted therapeutics such as Gleevec do (Capdeville et al., 2002; Druker, 2002) . Instead, a critical role in cellular proliferation (for review, see Grandori et al., 2000) . Induced rapidly upon entry into the cell cycle, MYC they would target an oncogene-dependent sensitivity. Such a strategy represents a pharmacogenetic approach analogous to expression is sufficient to drive quiescent cells into proliferation. Although MYC was originally characterized as a human onco-the concept of genetic synthetic lethality (Hartwell et al., 1997) , a term that refers to nonviability resulting from the combined gene based on translocation of its genomic locus in Burkitt's lymphoma, subsequent evidence indicates that aberrant MYC presence of two mutations or alleles, neither of which by itself is sufficient to induce death. By analogy, the pharmacogenetic expression occurs by a wide range of mechanisms in a variety of different tumor types (Nesbit et al., 1999; Oster et al., 2002) . version of this concept would refer to a drug that does not affect wild-type cells, but induces lethality in cells carrying a specific Indeed, MYC has been proposed to be deregulated in a large percentage of human cancers, and its overexpression frequently genetic alteration, such as a MYC translocation or amplification (Reddy and Kaelin, 2002) . Currently, a handful of attempts to correlates with aggressive, poorly differentiated tumors and poor prognosis. Paradoxically, in addition to promoting prolifer-identify such genotype-specific agents have been reported, targeting cells that carry alterations in cancer-associated pathways ation, MYC is also capable of sensitizing cells to apoptotic cell death under certain conditions (Evan et al., 1992; Pelengaris et such as receptor-tyrosine kinase/RAS signaling pathways (Fantin et al., 2002; Torrance et al., 2001) and/or in the p53 or al ., 2002) . While the precise mechanism by which this occurs remains unclear, this ability is believed to result from the exis-retinoblastoma (pRB) tumor suppressor pathways (Dolma et al., 2003) . tence of cellular tumor suppressor mechanisms that are "hardwired" to restrain the growth of cells that have acquired onco-
The cytokine TRAIL (Tumor Necrosis Factor Related Apoptosis Inducing Ligand, also known as APO2L) has received genic mutations.
Because MYC is deregulated in many human tumors, its much attention as a potential cancer therapeutic because it is capable of inducing apoptosis in a wide variety of tumor cells ability to sensitize cells to apoptosis could potentially provide a therapeutic window that would allow MYC-overexpressing while sparing most normal cell types (reviewed in Ashkenazi, 2002; Ozoren and El-Deiry, 2003) . While the molecular basis for DR5-specific antagonistic monoclonal antibodies (mAbs) (Leverkus et al., 2003; Sprick et al., 2002) to block TRAIL-mediated this selectivity is unknown, TRAIL appears to play a role in immune surveillance against cancer (Smyth et al., 2003) , sug-killing ( Figure 1B) . The anti-DR4 mAb, HS101, failed to protect BJ-MYC from TRAIL-induced apoptosis. In contrast, the anti-gesting that one of its physiological functions is to recognize and eradicate tumor cells. A homotrimeric type II transmembrane DR5 mAb, HS201, strongly protected cells. Addition of both mAbs did not result in additional protection over that provided protein and member of the tumor necrosis factor (TNF) family of "death ligands," TRAIL induces apoptosis by engaging recep-by anti-DR5 alone, suggesting that TRAIL acts primarily through the DR5 receptor, but not DR4, to induce apoptosis in BJ-MYC tors on the cell surface and activating an intracellular cascade of cell death-inducing proteases known as caspases through cells.
Additional evidence in support of this conclusion was ob-both mitochondria-dependent and -independent pathways (Ashkenazi, 2002) . tained using independently isolated anti-DR4 and -DR5 mAbs (named DR4-A and DR5-A, respectively). In contrast to HS101 Five TRAIL receptors have been identified to date. Of these, the Death Receptors 4 (DR4, also known as TRAIL-R1, APO2) and HS201, these mAbs act as receptor agonists and are each capable of inducing apoptosis with similar efficiencies in TRAIL-and 5 (DR5, also known as TRAIL-R2, TRICK2, KILLER) contain cytoplasmic death domains and can facilitate activation of the sensitive HCT116 colon carcinoma cells (D.A.K. and M.N., unpublished data). Their specificity for their cognate receptors initiator caspase, caspase-8, while the others, the so-called decoy receptors DcR1, DcR2, and OPG, lack intact death do-allows the role of each receptor to be assessed independently of the other or of any potential protective effects by decoy mains (Ashkenazi, 2002; Ozoren and El-Deiry, 2003) . Functionally inactive, these decoy receptors can compete with DR4 and receptors (D.A.K. and M.N., unpublished data; Griffith et al., 1999; Ichikawa et al., 2001) . Similar to their response to TRAIL, DR5 for binding to TRAIL and may therefore protect some cell types from exposure to the TRAIL ligand.
BJ-MYC cells were dramatically sensitized to DR5-A, whereas BJ cells were largely resistant ( Figures 1C and 1D ). However, Here we show that agonists of DR5 can act as pharmacological agents that are synthetically lethal with MYC overexpres-both control and MYC-expressing cells were completely resistant to DR4-A, confirming that MYC sensitizes BJ cells to apo-sion, potently inducing apoptosis in human cells overexpressing the MYC oncogene, both in vitro and in tumor xenografts in vivo.
ptotic signaling through the DR5 receptor, but not through DR4.
The sensitivity of BJ-MYC to DR5-A was unlikely to be due These results identify MYC as a critical determinant of TRAIL's DR5-mediated tumor specificity and suggest that DR5 agonists to increased cell proliferation caused by MYC, because coexpression of the cyclin-dependent kinase inhibitor p27 KIP1 de-may be effective as MYC-selective cancer therapeutics.
creased cell cycle progression, yet did not abolish or reduce sensitivity to DR5-A (Supplemental Figure S1 at http://www.
Results
cancercell.org/cgi/content/full/5/5/501/DC1).
To determine whether the pharmacogenetic interaction be-MYC sensitizes normal human fibroblasts to TRAIL-induced apoptosis tween DR5 agonists and MYC deregulation is a general phenomenon in human cells, we tested three additional strains of MYC's ability to sensitize cells to apoptotic stimuli has been well documented, particularly in rodent fibroblasts (Pelengaris primary or genetically defined cells: two primary human fetal  lung fibroblasts, IMR90 and WI38, and a nontransformed human  et al., 2002) . However, some strains of normal human fibroblasts overexpressing MYC have been reported to resist apoptosis embryonic kidney epithelial cell line, HA1E, immortalized by expression of the telomerase catalytic subunit TERT and the under serum starvation conditions that are sufficient to induce cell death in rodent cells (Vafa et al., 2002) . To systematically SV40 large T antigen (SV40 LT). Each of these lines behaved similarly to BJ cells, being resistant to TRAIL ligand, DR5-A, examine MYC's ability to sensitize nontransformed human cells to apoptosis, we subjected BJ primary human foreskin fibro-and DR4-A in the absence of MYC overexpression ( Figure 2 ). However, their MYC-expressing counterparts were all highly blasts, as well as derivative cells, BJ-MYC, carrying a retrovirally introduced MYC oncogene, to a variety of apoptotic stimuli. Of sensitive to TRAIL and DR5-A, but not DR4-A, suggesting that MYC-induced sensitization to DR5 signaling is a general phe-the treatments tested, which included serum starvation, DNAdamaging chemotherapeutic drugs, ionizing radiation, and acti-nomenon occurring in human cells of both mesenchymal and epithelial origin. vators of the TNF, FAS, and TRAIL death receptor signaling pathways, only TRAIL was able to induce cell death selectively in BJ-MYC, causing Ͼ90% decrease in viability, while having MYC stimulates caspase-8 autocatalytic processing Both DR4 and DR5 are thought to transmit apoptotic signals in no effect on BJ cells infected with vector alone ( Figure 1A ). DNA-damaging agents and serum starvation also resulted in a similar manner (see Figure 3A ). In response to ligand binding, a death-inducing signaling complex (DISC) composed of trimeric decreases in viable cell counts when compared to untreated ligand, receptor, and the adaptor protein FADD rapidly recruits cells. However, these decreases were primarily due to cell cycle the initiator caspase procaspase-8 (Peter, 2000) . Proximity arrest rather than cell death, as determined by microscopic within the DISC facilitates dimerization of procaspase-8, reobservation of nuclear morphology and Hoechst 33342 staining sulting in activation and proteolytic self-processing (Boatright (data not shown), and were only very modestly enhanced by et al., 2003) . Active caspase-8 can, in cell types termed type I MYC overexpression ( Figure 1A) .
cells, directly cleave and activate downstream effector caspases such as caspase-3 that execute the apoptotic death program TRAIL acts through the DR5 receptor to induce apoptosis in MYC-overexpressing cells (Fulda et al., 2002; Scaffidi et al., 1998) . Alternatively, in type II cells, active caspase-8 is insufficient to directly activate effector To determine through which receptor(s) TRAIL acts to induce cell death in BJ-MYC cells, we tested the ability of DR4-and caspases, but instead cleaves the pro-apoptotic Bcl-2 family member Bid to its active form, tBid, which engages the mitochondrial, or intrinsic, cell death pathway (LeBlanc et al., 2002; Scaffidi et al., 1998) . This results in the release of pro-apoptotic factors such as cytochrome c and SMAC/DIABLO from the mitochondria and subsequent activation of caspase-9 and downstream effector caspases such as caspase-3. To explore the mechanistic basis for the synthetic lethal interaction between DR5-A and MYC, we examined the apoptotic signaling pathway in normal human fibroblasts in the presence or absence of ectopically expressed MYC. Upon DR5-A stimulation, vector-transduced IMR90 and WI38 fibroblasts showed no processing of any of the caspases examined ( Figure 3B ). In contrast, MYC-expressing cells rapidly initiated the caspase proteolytic cascade, resulting in processing of caspase-8, -9, and -3 and Bid within 4 hr. As Bid and caspase-9 act specifically in the mitochondrial pathway, the observed cleavage of these proteins suggests that apoptosis in these cells involved the engagement of the mitochondrial pathway. However, since cells lacking ectopic MYC expression did not exhibit autocatalytic processing of the initiator caspase, caspase-8, or cleavage of its substrate Bid, these results suggest a positive feedback loop that amplifies the apoptotic signal pression of cell death, accompanied by lack of detectable caspase-9 processing ( Figure 3D ), suggests that mitochondrial (see Figure 3A ). Thus, formally, the stimulation of caspase-8 processing by MYC, rather than being due to enhancement of apoptotic signaling was almost totally abolished by Bcl-xL. However, under these conditions, and thus in the absence of any autocatalytic activity at the DR5 DISC, could be due to enhancement of the mitochondrial pathway, as has been proposed to mitochondrial amplification loop, caspase-8 processing was still strongly stimulated by DR5-A in BJ-MYC cells ( Figure 3D ). These occur in rodent fibroblasts (Juin et al., 1999) . To exclude this possibility, we retrovirally introduced into BJ-MYC a cDNA en-results therefore suggest that MYC acts at the level of caspase-8 activation within the DR5 DISC. coding the anti-apoptotic Bcl-2 family member Bcl-xL, which inhibits apoptosis by negatively regulating mitochondrial mem-To obtain further evidence that enhancement of caspase-8 activity by MYC was independent of mitochondrial amplification, brane permeability, thereby preventing the release of pro-apoptotic factors. Bcl-xL strongly inhibited effector caspase activity we inhibited MYC transcriptional activity using a dominant-negative version of MYC, MADMYC, comprised of the transcrip-( Figure 3C ) and cell death ( Figure 1C ) in BJ-MYC cells, demonstrating that apoptosis is mitochondria dependent and proceeds tional repression domain of the MYC/MAX antagonist MAD fused to the DNA binding and dimerization domain of MYC by a type II mechanism in these cells. The near complete sup- (Berns et al., 1997) . Ectopic expression of MADMYC via trans-BJ-MYC cells were significantly protected from DR5-A ( Figure  4E ), arguing that sensitivity to DR5-A induced by MYC was fection resulted in up to 80% decreased transcription from a cotransfected MYC-responsive luciferase reporter construct mediated at least in part by the upregulation of DR5.
Although these results indicate that DR5 upregulation plays (data not shown) and strongly reduced sensitivity to DR5-A ( Figure 3E ). However, apoptosis induced by ectopic expression a vital role in MYC-induced sensitization to apoptosis, it is likely that MYC also sensitizes by other mechanisms (Juin et al., 1999 ; of the processed form of Bid, tBid, was completely insensitive to the inhibition of MYC transcriptional activity ( Figure 3E ). These Klefstrom et al., 2002) . This contention is supported by the fact that reducing DR5 levels using siRNA only partially protected results were observed using a MYC-expressing, immortalized derivative of BJ, BJELB-MYC, as well as the epithelial cell line BJ-MYC cells from DR5-A and that BJ-MYC cells are also susceptible to FAS-induced apoptosis if additionally sensitized HA1E-MYC, suggesting that in human cells, MYC acts upstream of Bid processing in the DR5 death receptor pathway.
by serum starvation (Supplemental Figure S4 at http://www. cancercell.org/cgi/content/full/5/5/501/DC1). However, since MADMYC was unable to inhibit tBid-induced apoptosis ( Figure  MYC Figure 4C ), suggesting that retroviral MADMYC expression. The increase in total DR5 protein levels resulted in increased cell surface DR5 receptor levels, they are direct transcriptional target genes of MYC (Fernandez et al., 2003) . as determined by flow cytometry on intact cells ( Figure 4B ). DR4, FAS, and TNF receptor 1 (TNFR1) surface levels all remained unaffected by MYC, demonstrating that MYC's effect upon cell DR5 agonists specifically kill MYC-expressing tumors in vitro and in vivo surface death receptor levels was specific to DR5.
To determine if MYC upregulates DR5 expression at the Hahn, Weinberg, and colleagues have demonstrated that a combination of three genetic elements is sufficient to fully con-RNA level, we assayed changes in DR5 transcript levels upon activation of an inducible MYC fusion protein, MYC-ER (Eilers vert a variety of human cell types from normalcy to malignancy. These elements include TERT, SV40 ER (the early region of DNA et al., 1989) . MYC-ER is a fusion between MYC and the estrogen receptor ligand binding domain, which sequesters MYC in an tumor virus SV40), and an activated allele of the proto-oncogene HRAS, HRAS-V12 (Elenbaas et al., 2001; Hahn et al., 1999) . inactive cytoplasmic complex unless stimulated with estrogens. Addition of the estrogen analog 4-hydroxytamoxifen (OHT) to SV40 ER encodes two proteins: one, SV40 LT, disrupts the cell's two principal tumor suppressor pathways, the p53 and BJ cells carrying a retrovirally encoded MYC-ER (BJ-MYCER cells) sensitized them to DR5-induced apoptosis (Supplemental pRB pathways, while the other, the small t antigen, contributes to tumorigenic conversion by interacting with protein phospha- Figure S3 at http://www.cancercell.org/cgi/content/full/5/5/ 501/DC1) and resulted in induction of DR5 transcript within 1 tase 2A (Hahn et al., 2002) .
To determine if MYC activation is able to confer sensitivity to hr of OHT addition, as determined by semiquantitative RT-PCR ( Figure 4C ), demonstrating that MYC induces DR5 at the RNA DR5 signaling in the context of a tumorigenic cell, we examined human BJ fibroblasts and HA1E embryonic kidney epithelial transcript level. Addition of OHT in BJ cells lacking MYC-ER did not result in DR5 induction.
cells that had been systematically transformed from normalcy to malignancy by the addition of these genetic elements. The To determine whether MYC directly induces DR5 transcription, we activated MYC-ER in the presence of the protein synthe-fully transformed versions of each cell type by these elements (named BJELR and HA1ER, respectively) were largely insensi-sis inhibitor cycloheximide (CHX). Whereas CHX did not prevent induction of the well-characterized direct MYC target gene tive to TRAIL and DR5-A ( Figure 5A ). However, upon introduction of an HA epitope-tagged MYC allele, MYCHA, these cells cyclin D2 (Bouchard et al., 1999) , it completely prevented DR5 induction by MYC-ER ( Figure 4C ), suggesting that activation of became strongly sensitized. These results demonstrate that within the cellular context of a transformed cell, as in normal DR5 by MYC occurs via an indirect mechanism. This conclusion is supported by the absence of canonical CA(C/T)GTG MYC cells, MYC overexpression sensitizes to DR5-mediated apoptotic signaling. binding sites (E-boxes) in the DR5 promoter (Yoshida et al., 2001) .
The introduction of TERT, SV40 ER, and HRAS-V12 into normal human cells renders them tumorigenic in immune-com-To determine the functional significance of DR5 receptor upregulation by MYC, we manipulated DR5 receptor levels by promised mice (Elenbaas et al., 2001; Hahn et al., 1999) . These cells therefore provided us with the opportunity to test MYC's siRNA-mediated gene knockdown. Although in general, siRNAmediated gene silencing was not as effective in primary cells ability to confer sensitivity to DR5-induced apoptosis in tumors growing in vivo, using completely genetically defined cells. Fully as in established tumor cell lines (data not shown), we were able to identify an siRNA directed against DR5 that was sufficient transformed BJELR cells, containing either MYCHA-expressing retrovirus (BJELR-MYCHA cells) or vector control retrovirus to knock down DR5 receptor levels on BJ-MYC cells to levels seen on BJ cells ( Figure 4D ). In the presence of DR5 siRNA, (BJELR-EGFP cells), gave rise to tumors with a latency of ap- proximately 4 weeks, irrespective of MYC status, upon subcuta-To determine if the efficacy of DR5-A against MYC-expressing tumors correlated with induction of apoptosis, we assayed neous injection in immune-deficient SCID-BEIGE mice. To determine the sensitivity of these tumors to DR5 signaling in vivo, caspase activity in tumors harvested from mice 8 hr after treatment with a single IP injection of DR5-A. BJELR-MYCHA, but we injected tumor-bearing mice intraperitoneally (IP) every second day with 100 g of DR5-A, for a total of 5 treatments. Upon not BJELR-EGFP tumors, showed strongly increased effector caspase activity in response to DR5-A ( Figure 5E ). This depen-completion of the treatments, 100% (8/8) of BJELR-MYCHA tumors had responded to DR5-A treatment, showing a net re-dence upon both MYC and DR5-A for induction of caspase activity could also be observed in tumors derived from the tu-duction in tumor volume (p ϭ 0.006, Figures 5B and 5C ). 50% (4/8) of these were no longer detectable after treatment, either morigenic kidney epithelial cell line HA1ER ( Figure 5E ). These results thus demonstrate, using genetically defined cells that visibly or by palpation. 38% (3/8) resulted in a complete response with no signs of relapse within 1 month of treatment differ only in their MYC status, that DR5 agonists can be used to induce apoptosis specifically in MYC-overexpressing tumors cessation ( Figure 5D ). In contrast, BJELR-EGFP-derived tumors lacking ectopic MYC did not show a statistically significant re-in vivo. sponse to DR5-A (p ϭ 0.16), and none of the tumors showed a net reduction in volume after treatment (0/5). Thus, despite MYC activity is required for DR5-induced apoptosis in tumor-derived cell lines having no significant effect on tumor latency or growth rate, ectopic MYC expression was highly significant in determining
The above results demonstrate the pharmacogenetic relationship between MYC and DR5 agonists in genetically engineered treatment outcome (p ϭ 0.0004). tumor cells. To determine if a similar relationship exists in natu-HCT116, demonstrated that inhibition of DR5-induced cell death rally arising human tumors, we introduced the dominant-negaby MADMYC was accompanied by decreased caspase-8 protive MADMYC allele into a number of TRAIL-sensitive human cessing ( Figure 6D ) and effector caspase activity ( Figure 6E ). tumor cell lines, including a cervical carcinoma (HeLa) and two This suggests that MYC is required at the same step in the colorectal carcinomas (HCT116, HCT15) . Each of the cell lines apoptotic cascade in tumor-derived cells as in genetically deexpressed MYC at levels comparable to IMR90-MYC and WI38fined tumorigenic cells, i.e., at the level of caspase-8 activation. MYC cells ( Figure 6A ). In each of the tumor cell lines, MADMYC
To confirm that MYC activity was required for caspase-8 autoprotected significantly against DR5-A treatment, with cell surcatalytic processing at the DR5 DISC, rather than for stimulation vival being greater than 90% ( Figure 6B ). Similar protection of a mitochondrial feedback loop (see Figure 3A) , we examined could also be observed when MYC activity was reduced using apoptotic signaling in a Bax Ϫ/Ϫ derivative of HCT116 (Zhang et siRNA-mediated gene knockdown ( Figure 6C) . Resistance was al., 2000) . The Bax deficiency incapacitates the mitochondrial unlikely to be due to decreased proliferation caused by reduced pathway and thus dramatically inhibits induction of effector cas-MYC activity, because introduction of the cyclin-dependent kipase activity ( Figure 6E ) and cell death (Figure 6B , center) by nase inhibitor p16 INK4a , which caused equal or more severe de-DR5-A in these cells. Even in the absence of mitochondrial creases in proliferation (Supplemental Figure S5 at http:// signaling, DR5-A strongly stimulated caspase-8 processing, www.cancercell.org/cgi/content/full/5/5/501/DC1), did not rewhich could be impaired by MADMYC ( Figure 6D ). Thus, in cells duce sensitivity to DR5-A ( Figure 6B ). MYC activity is thus critical derived from naturally arising tumors, as in genetically defined for sensitivity to DR5-induced apoptotic signaling in a variety cells, MYC activity is critical for DR5-induced apoptosis because of tumor cell lines.
Further characterization of one of the cell lines tested, it is required for efficient caspase-8 activation at the DR5 DISC.
MYC-induced sensitivity to DR5 agonists is p53 independent
DNA-damaging agents are capable of sensitizing cells to TRAILinduced apoptosis by upregulating DR5 in a p53-dependent fashion (Wu et al., 1997) . This suggests that under some circumstances, TRAIL-mediated cytotoxicity can be p53 dependent (Wang and El-Deiry, 2003) . Given that MYC upregulates DR5 levels via an indirect mechanism ( Figure 4C) , we sought to determine if MYC's effects required functional p53 by utilizing a derivative of HCT116 in which both p53 alleles have been knocked out by homologous recombination (HCT116 p53 Ϫ/Ϫ ; Bunz et al., 1999) . HCT116 p53 Ϫ/Ϫ and its isogenic p53 ϩ/ϩ parent display equivalent sensitivity to DR5-A, and in each cell line, this sensitivity is MYC dependent, as apoptosis could be suppressed by overexpression of MADMYC ( Figure 7A ). Furthermore, surface levels of DR5 receptor were similarly downregulated by MADMYC in both cell lines ( Figure 7B ), demonstrating that both MYC-dependent susceptibility to DR5-induced apoptosis and upregulation of DR5 receptor do not require p53 activity.
Further evidence in support of this conclusion was obtained using a dominant-negative tumor-associated allele of p53, p53-H175. Expression of p53-H175 was sufficient to bypass ␥ irradiation-induced cell cycle arrest (Supplemental Figure S6 at http:// www.cancercell.org/cgi/content/full/5/5/501/DC1). However, it did not abolish DR5 receptor upregulation or sensitization to DR5-A in IMR90 cells ( Figures 7C and 7D) or in BJ and WI-38 cells (data not shown). Experiments are currently in progress to determine the p53-independent mechanisms by which MYC induces DR5 and sensitizes to DR5-mediated apoptosis.
Discussion

Synthetic lethal targeting of MYC as a therapeutic strategy
Because of its potent oncogenic activity and widespread deregulation in tumors, MYC has long made a tempting target for anticancer drug development. However, attempts to chemically disrupt its function have met with limited success, due to the inherent difficulty of inhibiting transcription factors with small molecules. Here, we demonstrate and validate an alternative, Second, the oncogene being targeted need not be essential for tumor maintenance, or even causal for tumor formation. In a number of mouse tumor models, MYC activity has been shown to be continuously required for tumor maintenance, suggesting that directly targeting MYC function may be an effective therapeutic strategy (Felsher, 2003) . However, it is clear that in a mental system, control BJELR-EGFP cells formed tumors with equal efficiency and latency as BJELR-MYCHA, MYC deregulation was clearly not a causal prerequisite for tumor formation and may not have been essential for tumor maintenance. Yet MYC-expressing tumors could still be effectively targeted. Thus, synthetic lethal targeting of MYC may be an effective strategy against tumor types that frequently overexpress MYC but for which no essential role for MYC in tumor formation or maintenance has been established (Oster et al., 2002) .
Third, pharmacogenetic synthetic lethality has the potential to be used as an experimental approach to uncover novel or unappreciated functions of oncogenes, in much the same manner that synthetic lethal genetic interactions have been used to elucidate biochemical or developmental pathways. Accordingly, we have used this approach to uncover a novel mechanism by which MYC sensitizes human cells to apoptosis, by upregulation of the DR5 death receptor and stimulation of caspase-8 activity. Given these advantages, it appears likely that the pharmacogenetic synthetic lethal strategy will provide a valuable complementary approach to more conventional oncogene targeting in cancer drug discovery (Reddy and Kaelin, 2002) .
Bypassing tumor cells' ability to evade apoptosis
The ability to evade apoptosis is believed to be an obligatory attribute acquired during the course of tumor progression (Hanahan and Weinberg, 2000) . Since MYC has been reported to sensitize cells to many different apoptotic stimuli (Hueber et al., 1997; Klefstrom et al., 1997; Pelengaris et al., 2002) , under some circumstances, tumors that overexpress MYC may acquire broad resistance to apoptotic stimuli, and thus fail to respond to DR5 agonists. This appears to be the case in small cell lung carcinomas (Shivapurkar et al., 2002) and neuroblastomas (Teitz et al., 2000) , in which amplification of MYC or its homolog MYCN correlates with mutation or silencing of various DISC component-encoding genes, particularly Casp-8. Thus, in these tumor types, MYC overexpression actually inversely correlates with TRAIL sensitivity. This has been referred to as "the N-Myc para- to all tumor types, since the human tumor-derived cell lines we Retroviral p16 INK4a was used to control for proliferation. tested all displayed elevated MYC levels ( Figure 6A ), yet showed B: Flow cytometry analysis of DR5 receptor levels on the surface of p53 ϩ/ϩ MYC-dependent sensitivity to DR5-A ( Figure 6B ). In human tu- and Wiman, 2002), consistently express cell surface DR5 levels and are characteristically sensitive to TRAIL-induced apoptosis (Mouzakiti and Packham, 2003) .
That DR5 agonists might be successfully used to eliminate subset of tumors, this dependence can be lost during the course MYC-positive tumors in human patients is perhaps most strikof tumor progression, giving rise to tumors that no longer require ingly illustrated by the in vivo response of BJELR-MYCHA-MYC expression for their continued growth and survival (D'Cruz derived tumors to DR5-A treatment. These tumors, which have et Karlsson et al., 2003) . Directly targeting MYC activity severely impaired p53 function due to inactivation by SV40 LT, by definition contain the genetic alterations necessary to resist in such tumors would likely be ineffective. Since in our experi-the apoptotic stimuli encountered during tumorigenesis, at least
The results presented here identify a synthetic lethal interaction between DR5 agonists and MYC and elucidate the mechain an immune-deficient animal. Yet despite their ability to evade nistic basis for this pharmacogenetic relationship. Importantly, apoptosis, they remain exquisitely sensitive to DR5 stimulation they demonstrate that this interaction can be therapeutically ( Figure 5 ). While subcutaneous xenograft tumor models have exploited to eradicate tumors in a genotype-selective fashion their limitations as predictors of clinical outcome-they typically in an animal model and thus validate DR5 agonists, as well as grow much more rapidly than spontaneously arising human the strategy of pharmacogenetic synthetic lethality, as feasible tumors, and thus often overestimate the ultimate clinical effects approaches to targeting MYC in human cancer. With the ongoof cytotoxic treatments (Sager and Lengauer, 2003)-the fact ing development of DR5 agonists as promising anticancer that isogenic BJELR-EGFP tumors lacking ectopic MYC grow drugs, MYC overexpression and its associated sensitization to in vivo at the same rate as BJELR-MYCHA, yet are insensitive apoptosis may prove to be an exploitable Achilles heel for many to DR5-A ( Figure 5C ), argues that it is the pharmacogenetic and human cancers. mechanistic interaction between DR5-A and MYC, rather than the rapid tumor growth rate, that underlies the observed treat- lines have provided little insight into the long unanswered ques-Tumor cell lines were grown as recommended by ATCC. IMR90 and WI38 tion of why TRAIL sensitivity frequently arises during the course were grown in Minimum Essential Medium Eagle (ATCC) supplemented with glutamine, penicillin/streptomycin, and 10% heat inactivated fetal bovine of tumorigenesis. Using defined genetic elements to systematiserum (FBS). HA1E-derived cells were grown in MEM-␣ medium supplecally convert human primary cells from normalcy to malignancy, mented as above. BJ-derived cells were grown in a mixture of DMEM/ we have dissociated MYC expression and sensitivity to DR5-Medium199 at a 4:1 ratio, supplemented as above but with 15% FBS. All mediated apoptotic signaling from the process of transformacells were grown at 37ЊC in a 5% CO 2 humidified incubator.
tion. We thereby demonstrate that DR5-mediated TRAIL sensitivity is acquired not as a necessary physiological consequence defects may also contribute to DR5 sensitivity. In fact, it has retroviruses; pWZLhygro was used for p53-H175 retrovirus; and LZRS-IRESbeen proposed that tumors are primed to respond to many EGFP was used for MYCHA retrovirus. 2 g/ml puromycin or 200 g/ml different apoptotic stimuli, including TRAIL signaling, by the hygromycin was used for selection. cumulative burden of their oncogenic load (Green and Evan, 2002) . In accordance with this hypothesis, it has been shown Antibodies Antibodies used for immunoblotting were obtained from the indicated suppli-that ectopic expression of proliferation-promoting genes such ers: MYC and Actin (Santa Cruz Biotechnology), caspase-8 and Bid (Becton as E2F1 can also sensitize human cells to death ligands, includ-Dickinson), DR5 (Cayman Chemical Company), caspase-9 (Cell Signaling), ing TRAIL (Phillips et al., 1999) and DR5-A (Y.W. and K.C.Q., and caspase-3 (R&D Systems). Anti-FAS functional antibody used was puriunpublished data), albeit moderately. However, E2F1 is unlikely fied IgM from clone CH11 (MBL International). DR4-A and DR5-A were to play a major role in determining sensitivity to DR5 agonists in mouse IgG 1 mAbs and will be described in greater detail elsewhere (D.A.K. human tumors. In human cancer, E2F activity is most frequently and M.N., unpublished data). For in vitro apoptosis assays, these mAbs were crosslinked by incubating them for 1 hr at room temperature, at a 1:3 deregulated by loss of one of its upstream negative regulators, ratio by weight with F(Ab') 2 fragment goat anti-mouse anti-Fc␥ (Jackson p16 INK4a , and to a lesser extent pRB, yet inactivation of pRB ImmunoResearch). function by SV40 LT failed to sensitize either HA1ER or BJELR cells to DR5-A or TRAIL, in vitro or in vivo ( Figure 5 ). Furthermore, Cell death assays re-introduction of p16 INK4a into 2 tumor cell lines that lack its Three thousand to ten thousand cells per well were plated in 96-well plates expression, HCT116 and HCT15, inhibited proliferation (Supplein the appropriate cell culture medium, allowed to attach overnight, and treated with various apoptotic stimuli for 16 hr. TRAIL preparations used:
mental Figure S5 and 6C), suggesting that MYC, but not E2F activity, plays a are not indicated, the following doses were used: Super Killer TRAIL (200 major and critical role in determining the sensitivity of these ng/ml), TNF␣ (100 ng/ml), CH11 anti-FAS (2 g/ml), ␥-irradiation (20 Gy), cisplatin (20 M), etoposide (50 M). Cell viability assays were performed tumor cells to DR5 agonists. in triplicate using CellTiter-Glo (Promega) according to the manufacturer's and Jeff Irelan, Garret Hampton, and Pedro Aza-Blanc for critical reading of the manuscript. instructions.
Transient transfections HA1E-MYC or BJELB-MYC (BJ-MYC cells immortalized with SV40 LT and
